Sensorion (FRA:RFM) Research & Development: €28.84 Mil (TTM As of Dec. 2025)


FRA:RFM Sensorion SA FRA:RFM
24 GF Score
Price €0.19
! 1 Warning Sign
View Full Analysis

What is Sensorion Research & Development?

Sensorion FRA:RFM -4.28% 24 Research & Development is €28.84 Mil as of Dec. 2025. GuruFocus rates FRA:RFM with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Sensorion's Research & Development for the six months ended in Dec. 2025 was €13.84 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €28.84 Mil.

Sensorion  (FRA:RFM) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Sensorion Research & Development Related Terms

Sensorion Research & Development Historical Data

* Premium members only.

The historical data trend for Sensorion's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sensorion Research & Development Chart

Sensorion Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.62 22.93 22.76 25.66 28.84

Sensorion Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.48 14.66 11.00 15.00 13.84
FRA:RFM
24GF Score
Sensorion SA FRA:RFM
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sensorion Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €28.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €28.84 Mil mean?
Sensorion (FRA:RFM) has a Research & Development of €28.84 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Sensorion and its competitors.
Is Sensorion's Research & Development too high?
Sensorion's current Research & Development is €28.84 Mil. Overall, Sensorion has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Sensorion's Research & Development compare to VRTX and REGN?
Sensorion's Research & Development of €28.84 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Sensorion and its competitors. Sensorion's current Research & Development is €28.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sensorion stock overvalued right now?
Sensorion (FRA:RFM) has a current Research & Development of €28.84 Mil. The current Research & Development is €28.84 Mil. Sensorion's overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Sensorion (FRA:RFM), the current Research & Development is €28.84 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sensorion Business Description

Other Exchanges ALSEN:FranceRFM:Germany
Address 375, rue du Professeur Joseph Blayac, Montpellier, FRA, 34080
Sensorion SA is a France-based clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders. The SENS501 (OTOF-GT) targets deafness caused by mutations of the gene encoding for otoferlin and is currently developed in a Phase 1/2 clinical study, and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. The company's pipeline programs are OTOF-GT (SENS-501), GJB2-GT, GJB2-GT, GJB2-GT, TREAT AND PREVENT, SENS-401 COCHLEAR, SENS-401 CIO, and SENS-401 SSNHL.
24GF Score

Get the complete analysis for FRA:RFM

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.19
Price